MDGLMadrigal Pharmaceuticals, Inc.
$433.63-1.9% 1Y
$433.63
$412.3552 weeks$602.83
Is the business good?
How good a business is MDGL?
Madrigal Pharmaceuticals, Inc. keeps −25% of every revenue dollar as operating profit, against −82% for the median Biotechnology name.
−25%
Operating margin · Biotechnology median −82% · 12 months to Q2 2026
- Share count, year on year
- +3.2%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 38%
R&D as % of revenue
Details›
- Operating margin12 months to Q2 2026
- −25%
- Net margin12 months to Q2 2026
- −25%
- Free cash flow margin
- −16%
- R&D as % of revenue
- 38%
- Revenue, trailing twelve months
- $1.28B
- Free cash flow, trailing twelve months
- −$207M
- Net income, trailing twelve months
- −$325M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
On our screens:Most shorted stocks